|
WDR55 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.31009999515541E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.45710000024557E-07 |
| Normal-vs-Stage2 |
1.215570E-02 |
| Normal-vs-Stage3 |
2.39059999995739E-06 |
| Normal-vs-Stage4 |
2.14119999999429E-05 |
| Stage1-vs-Stage2 |
5.853600E-01 |
| Stage1-vs-Stage3 |
5.452800E-01 |
| Stage1-vs-Stage4 |
3.500300E-02 |
| Stage2-vs-Stage3 |
3.530200E-01 |
| Stage2-vs-Stage4 |
5.900400E-02 |
| Stage3-vs-Stage4 |
1.673980E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.72350000937627E-09 |
| Normal-vs-AfricanAmerican |
1.704150E-03 |
| Normal-vs-Asian |
2.184200E-04 |
| Caucasian-vs-AfricanAmerican |
7.642200E-01 |
| Caucasian-vs-Asian |
6.173000E-01 |
| AfricanAmerican-vs-Asian |
5.365400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.16360000038618E-07 |
| Normal-vs-Female |
9.37220000496453E-08 |
| Male-vs-Female |
4.611000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.46840000048165E-07 |
| Normal-vs-Age(41-60Yrs) |
2.8028999999874E-06 |
| Normal-vs-Age(61-80Yrs) |
9.92170000000403E-05 |
| Normal-vs-Age(81-100Yrs) |
9.172000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.838600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.543600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.840400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.061000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.648400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.887400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.963800E-01 |
| Classical-VS-Follicular |
9.05775454640434E-12 |
| Classical-VS-Other |
5.191700E-02 |
| Classical-VS-Normal |
6.87239154473218E-12 |
| Tall-VS-Follicular |
2.15360000055398E-07 |
| Tall-VS-Other |
1.356460E-02 |
| Tall-VS-Normal |
1.27699999996622E-06 |
| Follicular-VS-Other |
7.398000E-01 |
| Follicular-VS-Normal |
6.239200E-01 |
| Other-VS-Normal |
8.320400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.214100E-04 |
| Normal-vs-N1 |
1.324950E-03 |
| N0-vs-N1 |
1.474950E-01 |
|
|
